Timeframe: 2010 – 2014 Goal: Assess potential of everolimus (RAD001) as a treatment option for FLC Principal Investigator: Ghassan Abou-Alfa, MD Study background and overview: At the time of this trial, the molecular drive of fibrolamellar, the DNAJB1-PRKACA fusion gene, had not been identified. However, several factors suggested that estrogen and estrogen-dependent pathways may play …
Timeframe: 2010 – 2011 Goal: Profile microRNA in metastatic fibrolamellar carcinoma Principal Investigator: Yuzhou Wang, PhD Study overview: MicroRNAs are small RNA species that regulate the expression of other genes and are important in many biological processes, including tumor development, growth, and metastasis. MicroRNAs have become increasingly useful as diagnostic markers, prognostic indicators, and therapeutic …
Timeframe: 2010 Goal: Identify biomarkers for FLC Principal Investigator: Michael Torbenson, MD (Currently at Mayo Clinic) Study overview: Early identification of tumors is essential for aggressive treatment. The majority of fibrolamellar carcinoma (FLC) patients have metastatic disease at the time of diagnosis. Therefore, identification of biomarkers for FLC is essential. Using a broad collection of …